诺诚健华与Prolium签署独占许可协议 最高可获5.025亿美元里程碑付款

财中社
20 Jan

财中社1月20日电诺诚健华(688428/09969)发布公告,近日,公司子公司北京诺诚健华医药科技有限公司、成都康诺亚生物医药科技(成都)有限公司以及北京天诺健成医药科技有限公司与Prolium签订了独占许可协议,授予Prolium在全球非肿瘤领域及除亚洲以外的全球肿瘤领域开展ICP-B02(CM355)即CD20×CD3双特异性抗体的开发、注册、生产和商业化的独占权利。根据协议,北京诺诚健华和...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10